DK1663182T3 - Hurtigt opløsende formulering af cinacalcet HCl - Google Patents

Hurtigt opløsende formulering af cinacalcet HCl

Info

Publication number
DK1663182T3
DK1663182T3 DK04781429.8T DK04781429T DK1663182T3 DK 1663182 T3 DK1663182 T3 DK 1663182T3 DK 04781429 T DK04781429 T DK 04781429T DK 1663182 T3 DK1663182 T3 DK 1663182T3
Authority
DK
Denmark
Prior art keywords
fast dissolving
cinacalcet hcl
dissolving formulation
formulation
cinacalcet
Prior art date
Application number
DK04781429.8T
Other languages
English (en)
Other versions
DK1663182T4 (da
Inventor
Francisco J Alvarez
Glen Gary Lawrence
Hung-Ren H Lin
Tzuchi R Ju
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1663182(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DK1663182T3 publication Critical patent/DK1663182T3/da
Application granted granted Critical
Publication of DK1663182T4 publication Critical patent/DK1663182T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04781429.8T 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet HCI DK1663182T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Publications (2)

Publication Number Publication Date
DK1663182T3 true DK1663182T3 (da) 2013-04-15
DK1663182T4 DK1663182T4 (da) 2020-02-17

Family

ID=34434844

Family Applications (6)

Application Number Title Priority Date Filing Date
DK04781429.8T DK1663182T4 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet HCI
DK14163366.9T DK2821067T3 (da) 2003-09-12 2004-09-10 Hurtigopløsningsformulering af cinacalcet
DK17185704.8T DK3260117T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
DK18175499.5T DK3395340T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK18175497.9T DK3395339T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK18175495.3T DK3395338T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl

Family Applications After (5)

Application Number Title Priority Date Filing Date
DK14163366.9T DK2821067T3 (da) 2003-09-12 2004-09-10 Hurtigopløsningsformulering af cinacalcet
DK17185704.8T DK3260117T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
DK18175499.5T DK3395340T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK18175497.9T DK3395339T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl
DK18175495.3T DK3395338T3 (da) 2003-09-12 2004-09-10 Hurtigt opløsende formulering af cinacalcet-hcl

Country Status (30)

Country Link
US (7) US7829595B2 (da)
EP (8) EP2821067B1 (da)
JP (3) JP5026077B2 (da)
KR (1) KR101332058B1 (da)
CN (1) CN1946382B (da)
AR (1) AR045637A1 (da)
AU (1) AU2004279318C1 (da)
BR (2) BR122018013029B1 (da)
CA (1) CA2536487C (da)
CY (5) CY1119609T1 (da)
DE (1) DE19164145T1 (da)
DK (6) DK1663182T4 (da)
EA (1) EA013425B1 (da)
ES (7) ES2737348T3 (da)
HR (1) HRP20130114T4 (da)
HU (5) HUE044822T2 (da)
IL (1) IL173737A (da)
IS (1) IS3027B (da)
MX (1) MXPA06002616A (da)
MY (1) MY142046A (da)
NO (1) NO335739B1 (da)
NZ (1) NZ545498A (da)
PL (6) PL1663182T5 (da)
PT (6) PT3395340T (da)
SG (1) SG146608A1 (da)
SI (6) SI1663182T2 (da)
TR (4) TR201909267T4 (da)
TW (1) TWI344363B (da)
WO (1) WO2005034928A1 (da)
ZA (1) ZA200602710B (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
DK1663182T4 (da) 2003-09-12 2020-02-17 Amgen Inc Hurtigt opløsende formulering af cinacalcet HCI
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
CA2603145A1 (en) * 2005-05-16 2006-11-23 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet hydrochloride
EP1883618B1 (en) * 2005-05-23 2009-10-14 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
EP1883625A2 (en) * 2005-05-23 2008-02-06 Teva Pharmaceutical Industries Ltd Amorphous cinacalcet hydrochloride and preparation thereof
AU2006250340C1 (en) 2005-05-26 2014-06-12 Sumitomo Pharma Co., Ltd. Pharmaceutical composition
EP1937233B1 (en) * 2005-09-02 2013-01-09 Amgen Inc. Modulating intestinal fluid balance using calcimimetics
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
US7393967B2 (en) * 2006-04-27 2008-07-01 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
US7449603B2 (en) * 2006-04-27 2008-11-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
DK3357496T3 (da) 2006-06-21 2020-05-11 Opko Ireland Global Holdings Ltd Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
CA2662315A1 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Solid composites of a calcium receptor-active compound
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
ES2956794T3 (es) 2007-04-25 2023-12-28 Eirgen Pharma Ltd Liberación controlada de 25-hidroxivitamina D
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
JP5358566B2 (ja) * 2007-06-21 2013-12-04 アムジエン・インコーポレーテツド シナカルセトおよびその塩を合成する方法
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
EP2300415A2 (en) * 2008-05-05 2011-03-30 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
ES2393067T3 (es) 2008-09-25 2012-12-18 Ratiopharm Gmbh Cinacalcet compactado
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8765676B2 (en) 2009-05-27 2014-07-01 Leo Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010136035A2 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
EP3636280A1 (en) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
EP2603215A4 (en) 2010-08-11 2015-08-05 Philadelphia Health & Educatio NEW DOPAMINERGIC D3 RECEPTOR AGONISTS FOR TREATING DYSKINESIA IN PARKINSON'S DISEASE
US20140147497A1 (en) * 2010-11-23 2014-05-29 Amgen Inc. Pediatric formulation
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
WO2012069402A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
EP2643290A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
EP2643292A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
AU2012364736A1 (en) * 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013107503A1 (en) 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
PL2730279T3 (pl) * 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
US9895325B2 (en) * 2012-12-21 2018-02-20 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
EP3985024A1 (en) 2013-02-01 2022-04-20 Atara Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2915432C (en) 2013-06-26 2019-03-05 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
WO2015136329A1 (en) * 2014-03-14 2015-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
JPWO2017170858A1 (ja) 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
WO2019034981A1 (en) * 2017-08-16 2019-02-21 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING CINACALCET CHLORHYDRATE AND ONE OR MORE BINDERS
US20210030671A1 (en) 2018-03-30 2021-02-04 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
MX2022010675A (es) * 2020-02-29 2022-09-23 Kempharm Inc Composiciones que comprenden profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IL88150A0 (en) 1987-11-02 1989-06-30 Merck & Co Inc Pharmaceutical tablet compositions containing phthalizine acetic acid compounds
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
ZA899071B (en) 1988-11-30 1990-08-29 Schering Corp Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
DE69433714T2 (de) 1991-08-23 2005-03-31 NPS Pharmaceuticals, Inc., Salt Lake City Kalzium - receptor aktive arylalkylamine
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
JP2728564B2 (ja) 1991-08-23 1998-03-18 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド カルシウム受容体活性化分子
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
KR100296899B1 (ko) 1993-02-23 2001-10-24 쉘비 칼베르그 모르스 칼슘수용체활성분자
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
PL181304B1 (pl) * 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
PT907631E (pt) 1996-05-01 2003-10-31 Nps Pharma Inc Compostos inorganicos activos como receptores de ioes
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
KR100771092B1 (ko) 1996-07-08 2007-10-30 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
JP2002505269A (ja) 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
CA2347092A1 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
DE69920035T2 (de) * 1998-11-23 2005-09-15 Monsanto Technology Llc. Hochkonzentrierte wässrige glyphosatzusammensetzungen
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
MXPA02006150A (es) * 1999-12-22 2004-09-06 Pharmacia Corp Formulaciones de liberacion sostenida de un inhibidor de ciclooxigenasa-2.
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
CA2423329A1 (en) 2000-09-22 2003-03-20 Takeda Chemical Industries, Ltd. Solid preparations
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (da) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
WO2003086343A2 (en) 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
TW200412956A (en) 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
DK1663182T4 (da) * 2003-09-12 2020-02-17 Amgen Inc Hurtigt opløsende formulering af cinacalcet HCI
EP1713489B1 (en) 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
CA2717906C (en) 2008-03-11 2022-07-05 Jamu Alford System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
ZA200602710B (en) 2007-04-25
JP2012197280A (ja) 2012-10-18
SI1663182T1 (sl) 2013-05-31
TR201910180T4 (tr) 2019-07-22
PL1663182T5 (pl) 2020-07-27
US7829595B2 (en) 2010-11-09
PL3395340T3 (pl) 2019-10-31
IS3027B (is) 2021-03-15
ES2735216T3 (es) 2019-12-17
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
US9375405B2 (en) 2016-06-28
CA2536487A1 (en) 2005-04-21
ES2734057T3 (es) 2019-12-04
PL2821067T3 (pl) 2018-02-28
EP3395339B8 (en) 2019-12-11
PT3395338T (pt) 2019-07-23
NO20061640L (no) 2006-06-12
HUE044279T2 (hu) 2019-10-28
EP3395338A1 (en) 2018-10-31
CY1119609T1 (el) 2018-04-04
EP3578175B1 (en) 2022-11-30
EP3395340A1 (en) 2018-10-31
DK3395340T3 (da) 2019-07-15
US20200222340A1 (en) 2020-07-16
SG146608A1 (en) 2008-10-30
SI3395339T1 (sl) 2019-08-30
EP3395339A1 (en) 2018-10-31
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
SI1663182T2 (sl) 2020-02-28
EP1663182A1 (en) 2006-06-07
PL3395338T3 (pl) 2019-10-31
JP5026077B2 (ja) 2012-09-12
NO335739B1 (no) 2015-02-02
EP3260117A1 (en) 2017-12-27
SI3395338T1 (sl) 2019-08-30
IL173737A0 (en) 2006-07-05
PT1663182E (pt) 2013-03-14
TR201910177T4 (tr) 2019-08-21
WO2005034928A1 (en) 2005-04-21
DK1663182T4 (da) 2020-02-17
EP3395340B1 (en) 2019-04-17
BRPI0414254B8 (pt) 2021-05-25
CA2536487C (en) 2011-10-25
EP2316442A1 (en) 2011-05-04
MY142046A (en) 2010-08-30
AU2004279318C1 (en) 2020-06-25
EP1663182B2 (en) 2019-11-20
BRPI0414254A (pt) 2006-11-07
EP3260117B8 (en) 2019-11-27
US20110136915A1 (en) 2011-06-09
PT3260117T (pt) 2019-07-04
SI2821067T1 (en) 2018-03-30
DE19164145T1 (de) 2021-04-29
PT3395340T (pt) 2019-07-15
EP2821067B1 (en) 2017-10-25
TW200518743A (en) 2005-06-16
CY1121812T1 (el) 2020-07-31
AU2004279318B2 (en) 2010-02-25
ES2737348T3 (es) 2020-01-13
JP5940120B2 (ja) 2016-06-29
EA200600566A1 (ru) 2006-08-25
HUE044822T2 (hu) 2019-11-28
PT2821067T (pt) 2017-12-01
EA013425B1 (ru) 2010-04-30
ES2735226T3 (es) 2019-12-17
BRPI0414254B1 (pt) 2021-03-02
CN1946382B (zh) 2010-12-08
ES2401769T3 (es) 2013-04-24
EP3260117B1 (en) 2019-04-17
DK3395338T3 (da) 2019-07-22
HRP20130114T1 (en) 2013-03-31
HUE035596T2 (en) 2018-05-28
JP5849015B2 (ja) 2016-01-27
PL3395339T3 (pl) 2019-09-30
ES2812198T1 (es) 2021-03-16
IL173737A (en) 2012-04-30
US20050147669A1 (en) 2005-07-07
EP3395339B1 (en) 2019-04-17
ES2655435T3 (es) 2018-02-20
EP3395340B8 (en) 2019-12-11
US20190117592A1 (en) 2019-04-25
CN1946382A (zh) 2007-04-11
EP2821067A1 (en) 2015-01-07
NZ545498A (en) 2010-04-30
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
SI3395340T1 (sl) 2019-08-30
AU2004279318A1 (en) 2005-04-21
SI3260117T1 (sl) 2019-08-30
BR122018013029B1 (pt) 2022-04-12
JP2007505108A (ja) 2007-03-08
TR201910447T4 (tr) 2019-08-21
PL3260117T3 (pl) 2019-10-31
IS8324A (is) 2006-02-23
PT3395339T (pt) 2019-07-15
US20180243238A1 (en) 2018-08-30
CY1121814T1 (el) 2020-07-31
US20160338975A1 (en) 2016-11-24
TWI344363B (en) 2011-07-01
DK3260117T3 (da) 2019-07-01
AR045637A1 (es) 2005-11-02
JP2015007089A (ja) 2015-01-15
CY1122259T1 (el) 2020-11-25
US20210052518A1 (en) 2021-02-25
PL1663182T3 (pl) 2013-06-28
EP3395338B1 (en) 2019-05-01
HUE045411T2 (hu) 2019-12-30
KR20070017460A (ko) 2007-02-12
TR201909267T4 (tr) 2019-07-22
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
DK2821067T3 (da) 2017-12-04
DK3395339T3 (da) 2019-07-22

Similar Documents

Publication Publication Date Title
DK1663182T3 (da) Hurtigt opløsende formulering af cinacalcet HCl
DK2172205T3 (da) Farmaceutisk formulering bestående af lanthan-forbindelser
NO20054868D0 (no) CaSr antagonist
DK3536344T3 (da) Superfin formoterolformulering
DE502004001561D1 (de) Kamera
DK1725123T3 (da) Fremstilling af ekspanderede madcrackers
IS7924A (is) Setnar anilín afleiður
NO20060375L (no) Famasoytisk preparat
DE602004017626D1 (de) Antistatische gegenstände aus schmelzeverarbeitbaren fluorpolymeren
ATE489359T1 (de) Amidoacetonitril-verbindungen gegen parasiten
DE502004001587D1 (de) Arretierelement
ITTO20040796A1 (it) Dispositivo di chiusura
SE0302861L (sv) Komparator
ATE395344T1 (de) Kalzilytische verbindungen
DK1611106T3 (da) Fremstilling af quinapril hydrochlorid
ITMI20030198A1 (it) Composizioni espandenti
ITMI20030641A1 (it) Composizioni espandibili di fluoropolimeri
ITBG20030020A1 (it) Dispositivo di aggancio
FI5931U1 (fi) Keskusyksikköteline
ES1055348Y (es) Mosqueton para escalada
ITMI20041369A1 (it) Dispositivo di chiusura
SE0301747D0 (sv) Låsanordning
SE0301471D0 (sv) Rörliga byggnadsställningar
TH0301001915B (th) สูตรผสมนาโนพาร์ทิคิวเลท ไฟเบรท
ITBS20040012A1 (it) Dispositivo di bloccaggio pezzo